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Mass Cytometry Defines Virus-Specific CD41 T Cells in
Influenza Vaccination
Priyanka B. Subrahmanyam,* Tyson H. Holmes,* Dongxia Lin,*,1 Laura F. Su,*,2 Gerlinde Obermoser,†,3 Jacques Banchereau,‡
Virginia Pascual,†,4 Adolfo Garcı´a-Sastre,§,{,k Randy A. Albrecht,§ Karolina Palucka,†,5 Mark M. Davis,* and Holden T. Maecker*

ABSTRACT
The antiviral response to influenza virus is complex and multifaceted, involving many immune cell subsets. There is an urgent need to
understand the role of CD4+ T cells, which orchestrate an effective antiviral response, to improve vaccine design strategies. In this
study, we analyzed PBMCs from human participants immunized with influenza vaccine, using high-dimensional single-cell proteomic
immune profiling by mass cytometry. Data were analyzed using a novel clustering algorithm, denoised ragged pruning, to define
possible influenza virus–specific clusters of CD4+ T cells. Denoised ragged pruning identified six clusters of cells. Among these, one
cluster (Cluster 3) was found to increase in abundance following stimulation with influenza virus peptide ex vivo. A separate cluster
(Cluster 4) was found to expand in abundance between days 0 and 7 postvaccination, indicating that it is vaccine responsive. We
examined the expression profiles of all six clusters to characterize their lineage, functionality, and possible role in the response to
influenza vaccine. Clusters 3 and 4 consisted of effector memory cells, with high CD154 expression. Cluster 3 expressed cytokines
like IL-2, IFN-g, and TNF-a, whereas Cluster 4 expressed IL-17. Interestingly, some participants had low abundance of Clusters 3 and
4, whereas others had higher abundance of one of these clusters compared with the other. Taken together, we present an approach
for identifying novel influenza virus–reactive CD4+ T cell subsets, a method that could help advance understanding of the immune
response to influenza, predict responsiveness to vaccines, and aid in better vaccine design. ImmunoHorizons, 2020, 4: 774–788.
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pruning (DRP, Fig. 1) for the speciﬁc purpose of determining
inﬂuenza virus–speciﬁc CD4+ T cell phenotypes.
Several algorithms are in use for clustering of data acquired via
mass cytometry [Table II in (20)]. DRP is specially designed to be
applicable in small datasets (i.e., low total cell counts) in two
important respects. First, DRP begins with a denoising step. A
prominent area of active research in CyTOF data analysis is noise
reduction, in which sources of noise are many and diverse (20).
Denoising can be especially useful in small datasets (21). Denoising
removes nonstructural variation in data without “selecting out”
any markers from the analysis. Clustering that includes marker
selection [e.g., as in (22)], although quite useful in general, is not
always applicable in mass cytometry studies because too few
rather than too many markers can be acquired, although in theory,
“high levels of multiplexing (.40 proteins in parallel) are possible”
(23). For example, ideally, the panel of markers in the current study
might have included more markers than just ICOS for deﬁnitively
identifying circulating Tfh cells. However, even a large CyTOF
staining panel cannot accommodate all phenotyping and functional markers needed for dissecting the broad immune
response reﬂected in peripheral blood. Second, as we demonstrate below, the DRP pruning algorithm permits isolation of
rare phenotypes. This property might distinguish DRP from the
related method of Citrus (24) because DRP includes an initial
denoising step, a diﬀerent method for ragged pruning (Fig. 1D),
and optimal pruning. Diﬀerential analysis of cydar is an
interesting alternative approach that may outperform Citrus
for detecting phenotypes (25), deterministic spanning-tree
progression analysis of density-normalized events (SPADE)
employs outlier removal and systematic downweighting to
facilitate detection of rare phenotypes (26), and X-shift’s
weighted k-nearest-neighbor density estimation algorithm has
been demonstrated to recover additional phenotypes not
identiﬁed via manual gating as well as transitional phenotypes
(27); however, neither cydar, SPADE, nor X-shift includes an
initial denoising step to facilitate resolution of phenotypic
structure, a step that may be crucial in the analysis of data
consisting of low total cell counts. Indeed, DRP is designed for
datasets containing (10,000 total cells.
The “denoised” component of the DRP algorithm (Fig. 1B)
isolates and removes noise from the signal intensity dataset prior
to clustering. Additionally, cell subsets of interest can vary
considerably in relative abundances (e.g., Fig. 2, vertical axis).
DRP’s “ragged-pruning” component (Fig. 1, Step D) permits
estimation of all distinct cell phenotypes, whether represented by
small or very large quantities of individual cells in the dataset.
Taken together, these two targeted properties make DRP
invaluable in the study of cell subsets that may be rare and of
subtle but distinct variations. Using DRP, we were able to
identify two relevant CD4+ T cell clusters from the CyTOF data,
one of which appears to be a pre-existing inﬂuenza virus–
speciﬁc cluster, and the other was an inﬂuenza vaccine–
responsive cluster. We further characterized expression proﬁles
of these clusters to understand their possible functional role in
the immune response to inﬂuenza virus.
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Inﬂuenza virus infection is a serious health concern, especially in
children, elderly patients, and those with respiratory disorders
or other chronic medical conditions. The inﬂuenza vaccine is
important to protect the general population from contracting the
disease and is especially critical for high-risk groups who will need
more frequent hospitalizations and suﬀer complications from
infection and even mortality. Unfortunately, the current inﬂuenza
vaccine must be developed, produced, and administered every
year, based on the predicted reassortment of viral strains for that
speciﬁc year. The eﬀectiveness of the vaccine can vary drastically
by viral strain from season to season and among diﬀerent age and
risk groups (1–3).
Conventionally, the immune response to inﬂuenza virus has
been characterized by the B cell–mediated production of virusspeciﬁc neutralizing or agglutinating IgG Abs. Hence, the
hemagglutination inhibition (HAI) assay is widely used to measure
protective immunity to inﬂuenza virus. Most vaccine development and evaluation has thus focused on this arm of the
immune system. However, in light of the limited eﬀectiveness
of the current inﬂuenza vaccine, there is a need to diversify
vaccine design approaches, possibly by including strategies for
T cell activation (4–7). To this end, there is great interest in
studying the role of T cells, especially CD4+ T cells, in the
generation and shaping of the immune response to inﬂuenza
virus (8–12). CD4+ T cells play a multifaceted role in the
antiviral response to inﬂuenza viruses, including the important
aspect of B cell help provided by T follicular helper (Tfh) cells
(13, 14). First, CD4+ T cells provide B cell help for the initiation
of germinal centers and the generation of high-aﬃnity Abs (15).
Furthermore, they are also important in the generation and
expansion of CD8+ memory T cell subsets, which can mount
eﬀective cytotoxic responses to virally infected cells (16, 17).
Finally, a subset of cytolytic CD4+ T cells have been shown to be
protective in inﬂuenza and could serve as an additional avenue to
boost the immune response (6, 18). Because CD4+ T cells are a
vastly heterogeneous population, it is imperative to identify
speciﬁc subsets that are key players in immunity to inﬂuenza
virus. The frequency of T cells speciﬁc for inﬂuenza virus Ags in
blood is low, making it important to determine that the cells being
studied are actually vaccine responsive, including those that arise
from naive T cells, as well as pre-existing memory T cells
generated during previous vaccination and/or exposure to inﬂuenza viruses (19). Such eﬀorts can eventually guide vaccine
design to create the next generation of more eﬀective and broadly
reactive inﬂuenza vaccines.
In this study, we performed a detailed phenotypic and functional
characterization of PBMCs from donors before vaccination (day 0)
and after vaccination (day 7) with trivalent inactivated inﬂuenza
vaccine (TIV). Using mass cytometry by time of ﬂight (CyTOF), we
were able to perform high-dimensional single-cell immune proﬁling,
with the goal of identifying inﬂuenza virus–speciﬁc immune cell
subsets. In this study, we used a novel method called denoised ragged
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MATERIALS AND METHODS

Sample selection
Blood samples were collected from 46 healthy donors prior to (day
0) and 7 d after (day 7) inﬂuenza vaccination. All study participants
were healthy donors, with samples collected under Institutional
Review Board–approved inﬂuenza vaccine studies at Stanford
University (SU; two separate studies) and Baylor Institute for
Immunology Research (BIIR; one study). Age range was 12–80 y
(median = 42 y); detailed age/gender information is shown in Table
I. All participants received the seasonal TIV during the period of
2009–2012.

CyTOF intracellular cytokine staining assay
Cells were stained and prepared for CyTOF analysis as previously
described (28). Brieﬂy, frozen PBMC samples from participants
were thawed and resuspended in complete medium (RPMI
1640 supplemented with 10% FBS, penicillin, streptomycin, and
L-glutamine) with benzonase. After washing, cells were counted,
and 2 3 106 cells (or maximum available) were placed in a 96-well
U-bottom plate in complete medium (benzonase-free). Cells were
rested overnight at 37°C and 5% CO2. Cells were then stimulated
for 8 h with 1 mg/ml each of hemagglutinin (HA) PepMix Inﬂuenza
A California H1N1 (139 peptides) and NP PepMix Inﬂuenza A
H3N2 (122 peptides), both from JPT Peptide Technologies (Berlin,
Germany). We chose this HA+NP peptide mix because although
current inactivated inﬂuenza virus vaccines are partly puriﬁed and
standardized for their HA content, there are some levels of NP
present in them. The secretion inhibitor monensin from Biolegend
(San Diego, CA), 2 mg/ml anti-CD40 from Miltenyi Biotec
(Bergisch Gladbach, Germany), and 1 mg/ml anti-CD28/CD49d

tree is then pruned back to create a set of clusters (circles of different
colors) that equal or exceed the first minimum cell count (e.g., illustrated in this study with minimum of four). (E) This pruning process is
repeated for each successively larger minimum cell count. (F) The
optimal cluster solution is from that minimum cell count of greatest
improvement in cluster quality relative to next smallest minimum cell
count. Together, (D) and (F) illustrate the formation of nested clusters
(see Materials and Methods). Actual trees will be many times larger than
FIGURE 1. Schematic representation of DRP algorithm.
(A) The original data matrix has individual cells as rows and cell surface

[103]. For this reason, DRP is computer-memory demanding. The figure

markers as columns. (B) A principal components analysis is performed

was generated using R package dendextend (64), R package MASS (65),

on this original data matrix, and the data matrix is denoised by hard

base R (43), and Microsoft PowerPoint and Word and Windows Paint

eigenvalue thresholding (red line). (C) An initial tree is created based on

(Microsoft Corporation, Redmond, WA). See Statistical Methods and

an agglomerative hierarchical clustering of the denoised data. (D) This

also see Section S1.2.2 in Bruggner et al. (24).

depicted in this study because total cell counts will equal or exceed O
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PBMC collection and storage
Heparinized blood was subjected to Ficoll-Hypaque gradient
separation, and PBMC were cryopreserved using standard
protocols. Samples collected at BIIR were shipped to SU on dry
ice, but all samples were otherwise stored in liquid nitrogen until
thawing for CyTOF analysis, as described below.
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FIGURE 2. Estimated proportions of all six clusters identified by DRP.
The estimated proportions of each cluster identified by DRP at day 0 and day 7 are represented graphically. Left panels show the influenza
peptide–stimulated condition, and right panels show the unstimulated condition. Each line represents a single study participant. *p , 0.05. Black
star symbols are estimated mean proportions for that cluster, stimulation condition, and day with the numeric values reported to four to five decimal
places. The estimates of mean proportions differ from Table III because they are without correction for regression covariates. The figure was
prepared in SAS ODS Graphics (SAS Institute).
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CyTOF data analysis
Raw data were obtained from CyTOF as .fcs ﬁles. Using the
calibration beads, these data were normalized for instrument
performance using the Nolan Lab MATLAB-based normalizer,
which is freely available on Github (https://github.com/nolanlab/
bead-normalization). Thereafter, the normalized .fcs ﬁles were
loaded into FlowJo (Version 9.9.4) from Tree Star (Ashland, OR).
Sequential gating of CyTOF data was performed as described
previously (28). Brieﬂy, gating on events positive for both DNA
markers 191Ir and 193Ir (DNA1 and DNA2) was used to identify
intact cells. DNA marker along with event length were used to
gate intact singlets. We then used 115In Maleimide-DOTA (a dead
cell stain) to gate on live intact singlets. Based on CD14 and CD33
expression, these live intact singlets were further gated into
lymphocytes (CD142CD332) and monocytes (CD14+CD33+). CD3
expression on lymphocytes was used to identify CD3+ T cells.
T cells were then gated as CD4+ and CD8+ (28). The CD4+ T cell
population from each sample was further analyzed for the
expression of ﬁve cytokines: IFN-g, IL-2, IL-17, TNF-a, and
MIP1b (Supplemental Fig. 1). Boolean logic was used to identify
cells that express any one or more of these ﬁve cytokines.
Expression data on all panel markers on each of these cytokine+
cells were exported and tabulated for further statistical
analysis as described below. Statistical analyses on these gated
cytokine+ CD4+ T cells were limited to 32 markers relevant to
T cells. The B cell marker CD19 and monocyte markers CD14
and CD33 were used for basic lineage gating but excluded from
further statistical analysis. Also, two poor-performing markers,

IL-10 and FOXP3, were excluded prior to the initiation of these
statistical analyses. The T cell–relevant markers used for
analysis were as follows: CXCR3, CCR6, CD57, CD69, CD4,
CD8, CD3, MIP1b, CD85j, CD45RA, CD38, TNF-a, Granzyme,
CD107a, GMCSF, CD154, IL-2, IFN-g, HLA-DR, Ki67, ICOS,
IL-17, CD127, CD27, CCR7, PD1, CXCR5, IL-21, Perforin, CD16,
CD56, and CD25.

Statistical methods
Cluster analysis. Separately for each of the 32 markers, raw
intensity data y were transformed as x = Arsinh[y5] and then
centered and scaled as t = (x 2 
x)/s for sample mean x and
corresponding sample SD s. Altogether, these transformed marker
data formed data matrix T (one column per marker, and one row
for each cell) for analysis (Fig. 1A). This data matrix T was used to
estimate cell clusters via the application of our newly developed
DRP clustering algorithm. DRP consists of ﬁve basic steps as
follows. 1) Denoising (Fig. 1B) was performed to separate structural
components (e.g., biological structure) from noise components
(e.g., technical error) (21). Structure was deﬁned as the principal
components of data matrix T with eigenvalues exceeding the
90th percentile of the null eigenvalue distribution (29). (Each
eigenvalue is the sample variance of its corresponding principal
component (30). Large eigenvalues indicate the presence of
structure in data. Null eigenvalues are small and arise from
structureless noise.) 2) Agglomerative hierarchical clustering (31),
a form of cluster analysis, was performed on the principal
components of large eigenvalues (i.e., structural principal components) of data matrix T (Fig. 1C). 3) The resultant hierarchical
clustering tree was “pruned” back in possibly ragged fashion (Fig.
1D). A tree is a graph (32) that, in this study, displays hierarchical
relationships among clusters of cells. The “branch tips” of the tree
are individual cells. Moving from the branch tips to the “trunk,”
clusters of cells are sequentially merged into larger and larger
clusters of more cells, ending at the trunk of the tree, in which all
cells have merged into a single cluster. Pruning the branches of this
tree creates pruned branch tips that, together, represent a set of
(merged) clusters, with each cell occurring in one cluster only. 4)
Pruning was repeated many times, each time with a progressively
larger criterion for minimum quantity of cells per “pruned
branched tip” (Fig. 1E). Minimum quantity of cells was varied
from 10 cells to ;20% of input sample size in increments of 50
cells. A set of cells are assigned to a cluster when they ﬁrst form a
branch with a quantity of cells equaling or exceeding the
minimum. For example, suppose the minimum size is four, and
two cells branch from an existing cluster of four cells. Those two
cells are assigned to their own cluster (e.g., two blue clusters in Fig.
1F) because 2 + 4 . 4. This facilitates discovery of rare phenotypes.
5) The ﬁnal step identiﬁed that pruning yielded a cluster solution
of the highest increase in average cluster quality (33) with an
increase in that minimum quantity of cells (Fig. 1E). Optimal
cluster solution is illustrated in a heat map of mean Arsinhtransformed expression by marker and cluster and in penalized
supervised star plots of Arsinh-transformed expression for all
markers together (34).
https://doi.org/10.4049/immunohorizons.1900097
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from BD Biosciences (San Jose, CA) were also added (the latter for
costimulation, the former to prevent CD40L downmodulation).
Anti-CD107a labeled with 154Sm (conjugated in-house) was also
added during stimulation to allow labeling of transiently expressed
CD107a. After 4 h, 5 mg/ml brefeldin A from Sigma-Aldrich (St.
Louis, MO) was added, and the plate was incubated for another
4 h at 37°C. Surface markers were stained using a mixture of metal
ion-conjugated Abs diluted in CyFACS buﬀer (metal-free PBS from
Rockland Immunochemicals [Pottstown, PA] with 0.1% BSA, 2 mM
EDTA, and 0.05% sodium azide) (Table II). Preconjugated Abs
from Fluidigm (South San Francisco, CA), as well as in-house
conjugated Abs, were included in the panel (Table II). 115In
Maleimide-DOTA from Macrocyclics (Plano, TX) was used for
LIVE/DEAD staining as per the supplier’s recommendations.
Cells were ﬁxed in 2% paraformaldehyde diluted in metal-free
PBS from Rockland Immunochemicals and permeabilized
using permeabilization buﬀer from eBioscience (Thermo
Fisher Scientiﬁc, Waltham, MA). These ﬁxed and permeabilized cells were stained using an intracellular Ab mixture
diluted in permeabilization buﬀer (Table II). Finally, cells were
stained with 191Ir and 193Ir DNA intercalator from Fluidigm, as
per the manufacturer’s directions. Samples were washed twice
in CyFACS and 3 times in Milli-Q water before running. EQ
Four Element Calibration beads from Fluidigm were added to
the sample as directed. Data were acquired on a CyTOF Version
1 instrument from Fluidigm.

ImmunoHorizons
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TABLE I. Age and gender distribution of participants in study
Age (y)
,30
30–39
40–49
50–59
60–69
.70
Total
% of total

Male

Female

Total

8
3
3
4
0
0
18
39.13%

7
3
9
7
1
1
28
60.87%

15
6
12
11
1
1
46
100.00%

Median age of the cohort was 42 y.

https://doi.org/10.4049/immunohorizons.1900097

TABLE II. CyTOF intracellular cytokine staining panel
Specificity

Metal Tag

Source

Dead cells
Beads
CXCR3
CCR6
CD19
CD57
CD69
CD4
CD8
CD3
MIP1b
CD85j
CD45RA
CD38
TNF
Granzyme
CD107a
GMCSF
CD154
IL-2
IFNg
HLA-DR
CD14
Ki67
FOXP3
ICOS
IL-17
CD127
IL-10
CD27
CD33
CCR7
PD1
CXCR5
IL-21
Perforin
CD16
CD56
CD25
DNA1
DNA2

115In
140Ce
139La
141Pr
142Nd
143Nd
144Nd
145Nd
146Nd
147Sm
148Nd
149Sm
150Nd
151Eu
152Sm
153Eu
154Sm
155Gd
156Gd
157Gd
158Gd
159Tb
160Gd
161Dy
162Dy
163Dy
164Dy
165Ho
166Er
167Er
168Er
169Tm
170Er
171Yb
172Yb
173Yb
174Yb
175Lu
176Yb
191Ir
193Ir

In-house
Fluidigm
In-house
Fluidigm
Fluidigm
In-house
In-house
Fluidigm
In-house
In-house
In-house
In-house
In-house
In-house
Fluidigm
In-house
In-house
In-house
In-house
In-house
In-house
In-house
Fluidigm
In-house
In-house
In-house
Fluidigm
In-house
Fluidigm
In-house
Fluidigm
In-house
In-house
In-house
Fluidigm
In-house
In-house
In-house
In-house
Fluidigm
Fluidigm

Nonprotein subjects are shown in italics. 115In-Maleimide-DOTA, a live-dead
stain, and 191Ir and 193Ir (DNA intercalators) are used to detect live intact singlets.
The calibration beads allow us to normalize data for instrument performance.

in more than one of the combined clusters because of the three
random downsamplings. We dropped any cells that occurred with
equal frequency in more than one cluster. For example, suppose a
cell was randomly selected in two downsamplings but assigned to
two diﬀerent major combined clusters; that cell was dropped. The
same rule applied to a cell assigned to three diﬀerent major
combined clusters. Together, these accounted for ;10% of the
15,015 cells. Any cell that only occurred in one major combined
cluster (11,187 cells, ;75%) was retained. Any cell that occurred in
one major combined cluster twice and a diﬀerent major combined
cluster once was retained for analysis (2279 cells, ;15%) and
assigned to that major combined cluster where it occurred twice
(majority vote). For each cell removed (numerator), we decreased
the total CD4 count (denominator) by one.

Downloaded from http://www.immunohorizons.org/ by guest on December 28, 2020

DRP reproducibility and computational speed. DRP’s pruning for
an optimal cluster solution is thorough and thereby computationally intensive. As such, we recommend running DRP on samples
sizes that do not exceed ;10,000 cells. We achieved these cell
counts through stratiﬁed random downsampling. Stratiﬁcation
was on each combination of study (two at SU and one at BIIR),
batch, participant, visit, and stimulation condition. Stratiﬁed
random sampling allowed us to achieve less inequality in cell
counts input to DRP such that all strata would be weighted less
unequally in the cluster solution (Supplemental Fig. 2A).
Speciﬁcally, within each stratum, sampling was random without
replacement (35) and with sample size per stratum being the
smaller of 88 cells or a sampling percentage of 90%. This rule
yielded a downsampling percentage of ;50% (i.e., approximately
half of all available cells were analyzed via DRP) per run of DRP.
The DRP algorithm was run on three separate stratiﬁed random
50% downsamplings to examine the reproducibility of results
across diﬀerent random downsamples. This resulted in three
separate DRP cluster solutions (Supplemental Fig. 2B). In
Supplemental Fig. 2B, for heat map labels at right, the ﬁrst
two digits are percentage of downsampling, third digit is
downsampling identiﬁcation number (1–3), and last digit(s)
is(are) DRP cluster identiﬁcation number within that downsampling (1, 2, 3, ...). Quantities of DRP clusters varied among
downsamplings, the highest at 18 clusters for the third downsampling. In dendrogram at left (Supplemental Fig. 2B), longer
horizontal line segments indicate greater separation in marker
expression among clusters at that level in the dendrogram.
Vertical yellow line was approximately placed where this
separation is greatest, and this line cuts the dendrogram in seven
places, yielding six major combined clusters. Seventh rare isolated
cluster marked by an “X” was excluded from further analyses
(Supplemental Fig. 2B). Clusters are termed “combined” because
of combining across closely related clusters from diﬀerent
downsamplings and combining closely related clusters within
the same downsampling, with all combining accomplished by
cutting the dendrogram at the vertical yellow line. Note that a
given cell may occur in more than one downsampling and that
admits the possibility that cells may occur in more than one of
these six major combined clusters. With all three downsamplings
combined and the one cluster marked with an X removed, the
dataset contained 15,015 cells with 3,828 cells (;25%) appearing
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TABLE III. Complete list of estimated proportions of all clusters across both time points and both stimulation conditions

Cluster

Stimulation
Condition

Estimate

0
0
7
7
0
0
7
7
0
0
7
7
0
0
7
7
0
0
7
7
0
0
7
7

Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim
Stim
Unstim

0.005287
0.004563
0.005154
0.004473
0.000204
0.000148
0.000199
0.000152
0.003910
0.001666
0.003798
0.001645
0.000253
0.000442
0.000292
0.000439
0.000029
0.000018
0.000029
0.000017
0.000099
0.000085
0.000093
0.000075

SE

Lower 95%
Confidence
Bound

Upper 95%
Confidence
Bound

0.000854
0.000921
0.000842
0.000900
0.000090
0.000065
0.000084
0.000068
0.001195
0.000547
0.001178
0.000550
0.000065
0.000131
0.000069
0.000125
0.000023
0.000015
0.000022
0.000014
0.000046
0.000045
0.000042
0.000037

0.003834995
0.003053719
0.003723868
0.002998645
0.000084928
0.000061416
0.000085881
0.000062763
0.002128751
0.000867630
0.002049616
0.000846333
0.000151905
0.000245043
0.000181568
0.000249725
0.000006284
0.000003307
0.000006295
0.000003317
0.000039411
0.000029555
0.000037480
0.000028068

0.007285690
0.006812640
0.007128893
0.006668867
0.000489135
0.000355026
0.000460072
0.000368067
0.007171356
0.003197555
0.007026867
0.003194069
0.000422264
0.000798285
0.000468155
0.000772443
0.000137423
0.000093301
0.000130341
0.000087339
0.000248397
0.000243408
0.000228578
0.000201457

Estimated mean proportions of total CD4+ T cells (and their SEs and 95% confidence intervals) by cluster, days elapsed following vaccination (day 0 or day 7), and
stimulation condition. Estimates were obtained from fit of regression model (see Statistical Methods); in contrast to Fig. 2, estimates have been adjusted for covariates.
Stim, stimulated with HA1NP peptide mix; Unstim, unstimulated.

Comparing cluster proportions. From the estimated optimal
cluster solution (Fig. 1F), numerators and denominators of cell
counts were tabulated. Numerator n was the cell count for each
combination of study, batch, participant, visit, stimulation condition, and cluster and zero for any such combination without cells.
Denominator d was the gated total CD4+ T cell count. These
yielded an estimated cluster proportion per combination of study,
batch, participant, visit, and stimulation condition of r = n/d. For
each cluster, sample sizes (of participants) were 48, 48, 47, and 47
for day 0 unstimulated, day 0 stimulated, day 7 unstimulated, and
day 7 stimulated, so two data values were missing. A regression
model was ﬁt separately for each cluster. Observed proportion r
was regressed on visit, stimulation condition, the interaction of
visit and stimulation condition, study (to account for any otherwise
unmeasured diﬀerences in the three sampled populations),
elapsed days from start of study for batch (batch day), and the
interaction of study and batch day. The interaction of visit and
condition allowed diﬀerences in cluster proportions between
conditions to vary with visit and the converse. The interaction of
study and batch day allowed any trends in proportions over time
across batches to vary among studies. Outcome r was modeled as
a binomial proportion; however, unlike a standard binomial
distribution in which the denominator is constant, the denominator d in this study varies among participants and stimulation
conditions within participants. For this reason, we employed
fractional logistic regression with a robust estimator of the
variance (36, 37) and random coeﬃcients (i.e., mixed-eﬀects

model) for participants. These random coeﬃcients are additional
predictor variables that account for participant-speciﬁc variation
in mean r not explained by visit, stimulation condition, the
interaction of visit and stimulation condition, study, batch day, and
the interaction of study and batch day. From the ﬁt of the
regression model, the average participant’s diﬀerence in means of
proportions r between 1) stimulation conditions within each visit
and 2) visits within each stimulation condition were estimated. All
p values were adjusted for multiple comparisons (38) across all
comparisons (i.e., visit comparisons combined with stimulation
comparisons for all clusters).
Cluster proportions association with clinical outcome. Separately
for each strain, HAI titer at day 28 was regressed on the stimulated
proportion of each cluster r at day 0 (baseline), study, and baseline
HAI titer. Baseline HAI titer was employed as a covariate rather
than formulating the outcome as fold change (day 28 divided by
baseline) to improve statistical power (39). Because a titer of h
indicates that true titer falls somewhere in the half-closed interval
[h, 2h), analysis employed regression methods for intervalcensored outcome data (40, 41). In a separate, secondary analysis,
for each strain, HAI titer at day 28 was regressed on the stimulated
proportion of each cluster r at day 7, study, and baseline HAI titer.
Missing CyTOF and HAI data were multiply imputed using fully
conditional speciﬁcation with predictive mean matching (42).
Fifty complete datasets were generated 1) with missing values for
HAI titer imputed using predictors of HAI strain, study, day 0, and
https://doi.org/10.4049/immunohorizons.1900097
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TABLE IV. All comparisons of mean cluster abundance between time points and between stimulation conditions
Cluster

Comparison of Proportions

Unadjusted p Value

FWE Adjusted p Value

Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0
Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0
Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0
Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0
Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0
Day 0 Stim minus Unstim
Day 7 Stim minus Unstim
Stim day 7 minus day 0
Unstim day 7 minus day 0

0.0640
0.0516
0.0047
0.0915
0.4473
0.4403
0.4842
0.7225
,0.0001
,0.0001
0.0306
0.3643
0.0193
0.0624
0.0009
0.8316
0.1595
0.1043
0.6446
0.3587
0.4075
0.2231
0.3127
0.1544

1.0000
0.9292
0.0987
1.0000
1.0000
1.0000
1.0000
1.0000
,0.0001
,0.0001
0.5811
1.0000
0.3865
1.0000
0.0203
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000

For each cluster, comparisons are of mean proportions of total CD4+ T cells between stimulation conditions within each day and, separately, between days within
each stimulation condition. Days are days elapsed since vaccination, and p values are reported without (unadjusted p value) and with (family-wise error adjusted
p value) correction for multiple comparisons. Comparisons were made from fit of regression model (see Statistical Methods).
FWE, family-wise error; Stim, stimulated with HA1NP peptide mix; Unstim, unstimulated.

day 7 proportions for all six clusters and 2) with missing values for
day 7 proportions of all six clusters imputed using predictors of HAI
strain, study, day 0 and day 28 HAI titers, and day 0 proportions for
all six clusters.
Software. Statistical analyses were performed in SAS (SAS Institute,
Cary, NC), base R (43), and R packages cwhmisc (44), WeightedCluster (45), heatmap3 (46), matrixcalc (47), plotrix (48), JPEN
(49), sampling (50), VCA (51), rospca (52), and tsne (53). Additional
software for generating graphics is listed in the ﬁgure legends.
RESULTS
We used mass cytometry (CyTOF) to examine the phenotypic and
functional markers of inﬂuenza virus–speciﬁc T cells prior to and
1 wk after vaccination with seasonal TIV (Tables I, II). PBMC were
unstimulated or stimulated with HA+NP overlapping peptides
prior to the CyTOF assay. CyTOF data were manually gated to
obtain cytokine+ (IFN-g, IL-2, IL-17, TNF-a, or MIP1b) CD4+
T cells (Supplemental Fig. 1). CyTOF panel marker expression data
for each of these cells were exported, and DRP was used to identify
inﬂuenza virus–speciﬁc CD4+ T cell clusters (Fig. 1).

Inﬂuenza virus–speciﬁc CD4+ T cell clusters identiﬁed
by DRP
Using the novel statistical method of DRP, we obtained an
optimized cluster solution for the cytokine+ CD4+ T cells. A total of
https://doi.org/10.4049/immunohorizons.1900097

six clusters were identiﬁed by this method (Fig. 2). A tabulated list
of estimated proportions of all six clusters at all time points and
stimulation conditions is shown in Table III. Table III clearly
quantiﬁes the extreme rarity of these phenotypes (e.g., stimulation
at 7 d postvaccination generates approximately two cells of Cluster
2 per 10,000 CD4+ T cells). At each time point, we compared the
abundance of each cluster in inﬂuenza virus peptide–stimulated
samples to their unstimulated counterparts. Cluster 3 was
signiﬁcantly higher in inﬂuenza peptide–stimulated versus–
unstimulated conditions (Table IV), suggesting that it is an
inﬂuenza virus–speciﬁc cluster. Cluster 3 was signiﬁcantly
higher in the stimulated condition at both day 0 and day 7; thus,
it appears to represent a memory T cell response to inﬂuenza
viruses (which may or may not have been increased by
vaccination). In contrast, Cluster 4 was signiﬁcantly higher at
day 7 after vaccination compared with day 0 in the inﬂuenza
peptide–stimulated condition (Fig. 2, Table IV). This indicates
that Cluster 4 is a vaccine-induced CD4+ T cell cluster that may
play an important role in the immune response to the virus. All
other clusters (Clusters 1, 2, 5, and 6) did not show signiﬁcant
diﬀerences between stimulated and unstimulated conditions or
between the two time points (Table IV). They thus represented
T cells that were cytokine producing, but not inﬂuenza virus
speciﬁc, or that were so rare (e.g., Cluster 6) and/or variable
among participants as to not reach statistically signiﬁcant
increases above their unstimulated background, given the
number of cells sampled. A complete list of all comparisons
across stimulation conditions and time points is shown in

Downloaded from http://www.immunohorizons.org/ by guest on December 28, 2020

1
1
1
1
2
2
2
2
3
3
3
3
4
4
4
4
5
5
5
5
6
6
6
6

782

CyTOF DEFINES INFLUENZA-SPECIFIC CD4+ T CELLS

ImmunoHorizons

Downloaded from http://www.immunohorizons.org/ by guest on December 28, 2020

FIGURE 3. Star plots of three of the six total clusters identified by DRP.
Star plots of Clusters 3, 4, and 6 show the expression of various markers represented in two-dimensional space. Individual cells from each cluster
are represented on the star plot as colored dots (3, blue; 4, green; and 6, magenta). Arrows indicate the expression of individual markers. Clockwise
from top left shows day 0 unstimulated, day 0 stimulated, day 7 stimulated, and day 7 unstimulated. Star plots were produced through stratified
random downsampling to 82 cells for each combination of cluster, visit, and condition, which allowed equal weighting of all three clusters for both
visits and both conditions. For this reason, these star plots can only be used to assess patterns in expression and not in abundance. Software
packages for producing star plots were base R plus R packages matrixcalc, plotrix, JPEN, sampling, and VCA, as indicated in the Materials and
Methods. Stim day 7 modified from Holmes et al. (34) with permission from Mary Ann Liebert, Inc., New Rochelle, NY. Stim, stimulated with HA1NP
peptide mix; Unstim, unstimulated.
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The heat map shows mean expression level [Arsinh (y/5), y = raw expression] across stimulation conditions and visits in color scale that
ranges from white (high) to black (low) for all markers on the panel
(labeled at bottom). Cluster label numbers are shown on the right. This
heat map allows approximate determination of the mean phenotypic
and functional characteristics of the cells that constitute the represented clusters. The heat map was produced with R package heatmap3,
as indicated in the Materials and Methods.

Table IV. Furthermore, a tabulated list of estimated proportions of all clusters at all time points and stimulation
conditions is shown in Table III. Table III quantiﬁes the
extreme rarity of these phenotypes (e.g., stimulation at
7 d postvaccination generates approximately two cells of
Cluster 2 per 10,000 CD4+ T cells).

Immunophenotypic characterization of inﬂuenza
virus–speciﬁc Clusters 3 and 4
Our data showed that Cluster 3 appeared to be inﬂuenza virus
speciﬁc in that it was signiﬁcantly more abundant with inﬂuenza
peptide stimulation versus the unstimulated condition at both time
points (Fig. 2, Tables III, IV). In contrast, Cluster 4 was vaccine
induced, as it was signiﬁcantly higher in the stimulated condition
at day 7 postvaccination compared with day 0. To explore the
phenotypic and functional diﬀerences between these clusters, we
created star plots (Fig. 3). These star plots are mainly used to assess
patterns in expression–qualitative diﬀerences beyond abundance.
From the star plots, it is apparent that Cluster 3 is very diﬀerent
from Cluster 4, mainly in its high expression of cytokines like
IFN-g and TNF-a with CD154 and CD127. Cluster 4, in
contrast, projects more along a complex combination of vectors
https://doi.org/10.4049/immunohorizons.1900097
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representing the CD25, CD45RA, CCR7, MIP1b, and GM-CSF,
although the precise expression patterns warrant additional
visualization methods. Another interesting observation was
that Cluster 6 appears to change between day 0 and day 7
postvaccination in both the unstimulated as well as stimulated
conditions. We see that Cluster 6 is spread out during the day
0 time point but starts to project along the lower left quadrant
that represents HLA-DR, perforin, and granzyme B postvaccination. Thus, Cluster 6 has undergone changes in its marker
expression proﬁle following inﬂuenza vaccination. However,
Cluster 6 did not signiﬁcantly change in abundance between
time points and stimulation conditions (Table IV).
To further characterize the diﬀerences between these inﬂuenza virus–speciﬁc clusters, we created a heat map of mean
marker intensity per cluster across stimulation conditions and
visits (Fig. 4). From this heat map, we could discern the major
markers distinguishing each cluster. The heat map allows the
visualization of all markers at once, but we have also shown the
cell-level distribution of expression (pooled across stimulation
conditions and visits) for major markers in the form of dot plots
(Fig. 5). Both Cluster 3 and 4 showed low expression of CCR7 and
CD45RA, indicating that these are most likely eﬀector memory
CD4+ T cell subsets (Figs. 4, 5A). Both clusters also showed high
expression of the activation marker CD154, which indicates an
ability to provide help via the CD40L/CD40 pathway (Figs. 4, 5D).
Cluster 3 showed high levels of IFN-g, TNF-a, and IL-2, in
addition to the low levels of CCR7 and CD45RA, suggesting that
these were functional, cytokine-producing eﬀector memory
CD4+ T cells (Figs. 4, 5B, 5C). Cluster 4 was also an eﬀector
memory-like subset and expressed high CD154 (Figs. 4, 5A,
5D). However, its cytokine proﬁle was very diﬀerent from
Cluster 3, with low levels of IFN-g, IL-2, and TNF-a and a high
level of IL-17 (Figs. 4, 5B, 5C). This indicates that Cluster 4 may
be a Th17-like eﬀector memory subset. Cluster 6 showed a high
expression of granzyme B and CD107a, in addition to HLA-DR
and cytokines IFN-g, MIP1b, and TNF-a (Fig. 4). Interestingly,
among the six total CD4+ T cell clusters identiﬁed, we observed
that some clusters showed cytotoxic markers. Clusters 2, 5, and
6 showed high CD107a levels, Clusters 5 and 6 had high
granzyme B, and Cluster 5 had high perforin expression (Fig.
4). This indicates that there are cytotoxic CD4+ T cell subsets
among the total cytokine-producing CD4+ T cells that we
analyzed in this study.

Distribution of clusters within individuals
We next investigated the distribution of Clusters 3 and 4 by study
participant to determine if there were any trends in the abundance
of the two clusters within an individual (Fig. 6). Some participants had negligible levels of both clusters. Another group of
participants had detectable levels of both clusters, but high
abundance of Cluster 3 and low abundance of Cluster 4. These
distinct subgroups with speciﬁc trends in the abundance of Cluster
3 and Cluster 4 reﬂect an underlying heterogeneity in individual
biology. However, abundance of Cluster 3 or Cluster 4 did not
correlate with HAI response to the vaccine (data not shown).
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The expression (raw intensity) of some important characterizing markers expressed by Cluster 3 (blue) and Cluster 4 (green) are shown in the form
of dot plots. Each dot is an individual cell. Markers shown are (A) CCR7 and CD45RA, (B) IL-2 and IFN-g, (C) IL-17 and TNF-a, and (D) CD154 and
ICOS. The figure was prepared in SAS ODS Graphics (SAS Institute).

DISCUSSION
With the advent of CyTOF, there has been a surge of single-cell
proteomic data on the phenotype and function of immune cells.
Having a staining panel of 37 diﬀerent Abs presents an invaluable
opportunity to discover novel cell subsets and understand their
biological role. However, analyzing this high-dimensional dataset
poses several challenges, which must be overcome by advanced
computational methods (54). The DRP method uses a multifaceted
approach consisting of denoising the input data, agglomerative
hierarchical clustering, and repeated pruning to obtain an
optimized cluster solution (Fig. 1).
Rather than denoising, Phenograph addresses the problem of
detecting rare phenotypes in noisy data using a two-step
procedure for construction of nearest-neighbor graphs (55). The
denoising step of DRP relies upon optimal selection of the
quantity of principal components to be retained for the
hierarchical clustering. Because principal components are linear
combinations of the marker intensity values, nonlinear dimension
reduction methods, such as t-distributed stochastic neighbor
embedding (56) and kernel-based density estimation extensions
such as automatic classiﬁcation of cellular expression by nonlinear stochastic embedding (57), might identify phenotypes not

recovered by DRP. In our experience, t-distributed stochastic
neighbor embedding did mostly provide clear recovery of subsets
in this study’s dataset (Supplemental Fig. 3). Further, we do
recommend and did apply a nonlinear transformation of the
marker intensity values prior to estimating principal components.
Although beyond the scope of the current study, direct
comparison of results from DRP and PhenoGraph in several
simulated and real small datasets (#10,000 cells in total) would be
highly instructive.
This study did not statistically correct acquired CyTOF data for
the nonspeciﬁc binding artifact of cross-reactivity. However, our
CyTOF panel has been optimally titrated as described (58) to
minimize nonspeciﬁc binding and spillover.
The DRP method described in this study allowed us to use
clustering to identify novel cell subsets and gain a deeper
understanding of their phenotypic and functional characteristics. Recall that a “sample estimate” is deﬁned as the value of a
parameter estimated from a sample drawn from a population (e.g.,
sample mean is an estimate of the population mean). The analysis
pipeline presented in this study ﬁrst estimates what clusters of
cells are present and, using those estimated clusters, then estimates
diﬀerences in the mean proportions of each of those clusters
between visits and between stimulation conditions. Note that the
https://doi.org/10.4049/immunohorizons.1900097
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The distribution of cluster abundance (square root of proportion of CD4+ T cells) for Clusters 3 and 4 is shown by participant, separately for each
combination of visit and stimulation condition. Each line represents a single study participant. Color-coding is by individual to show how the
abundance of cells differs between clusters for that individual. Square-root transformation (vertical axes) facilitates visual separation of individuals.
The figure was prepared in SAS ODS Graphics (SAS Institute). Stim, stimulated with HA+NP peptide mix; Unstim, unstimulated.

second set of estimates (diﬀerences in mean proportions) thereby
depends upon the ﬁrst set of estimates (cluster identities).
Especially rigorous control of type I error (false positives) would
propagate estimation (sampling) error in estimates of cluster
identities into subsequent estimates of diﬀerences in the mean
proportions of each of those clusters between visits and between
stimulation conditions. How to accomplish this error propagation
without resorting to computationally prohibitive methods requires
study and is beyond the scope of the present paper. As such, the
comparisons of each cluster’s mean proportions between visits and
between conditions that are reported in the present paper should
be regarded as liberal (i.e., reject the null hypothesis too often)
to some unknown extent. In this study, we focused on CD4+
T cells, whose role is not completely understood in the context of
inﬂuenza vaccination. Using DRP on our dataset, we identiﬁed two
cell clusters that either responded to inﬂuenza peptide stimulation or inﬂuenza vaccination (Fig. 2, Table IV). Cluster 3 was
signiﬁcantly above background at both day 0 and day 7, reﬂecting
pre-existing inﬂuenza virus–speciﬁc cells that presumably persisted from previous vaccination(s) or infection(s) (Table IV). The
abundance of Cluster 3 did not change between time points for
https://doi.org/10.4049/immunohorizons.1900097

either stimulation condition. Cluster 4, in contrast, was signiﬁcantly more abundant with stimulation at day 7 following
vaccination compared with stimulation at day 0 (prevaccination)
(Fig. 2, Table IV). However, the abundance of Cluster 4 did not
increase between the inﬂuenza peptide–stimulated condition and
the unstimulated condition at either time point. This implies that it
is a CD4+ T cell cluster that is responsive to inﬂuenza vaccination
but may not be responsive to the speciﬁc peptides used for
stimulation in our experiments. Alternatively, the p values (adjusted
for multiple comparisons) for stimulated versus unstimulated
conditions may have not been signiﬁcant because of the number
of cells sampled and/or because of stringent corrections for
multiple comparisons (Table IV).
Cluster 3, the pre-existing inﬂuenza virus–responsive CD4+
T cell subset, showed low CCR7 and CD45RA. This cluster
expressed cytokines like IL-2, TNF-a, and IFN-g, as well as high
levels of CD154 (Figs. 4, 5). This corresponds to a functionally
ready eﬀector memory subset that is present prior to TIV
immunization. The abundance and reactivity of this cluster may
depend on factors like previous vaccine experience and the Ag
exposure history of the participants.
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B. It is possible that our experimental limitations precluded the
identiﬁcation of changes in the abundance of Cluster 6 between
stimulation conditions and time points. Alternatively, the change
in the expression proﬁle of this cluster (Fig. 3) might be related to
changes taking place in other inﬂuenza-speciﬁc subsets. Without
knowing if Cluster 6 is inﬂuenza virus–speciﬁc or vaccine
responsive, it is diﬃcult to fully understand the implications of
its qualitative transformation following inﬂuenza vaccination.
However, given the marker expression proﬁle, it is interesting
to speculate that this could reﬂect a relationship between late
eﬀector CD4+ T cell accumulation in CMV-positive individuals and
poor response to inﬂuenza vaccine, as previously described (63).
In this study, statistical testing for diﬀerences in marker
expression levels was not performed because cluster analyses are
designed to segregate cells into clusters that are as distinctive as
possible with respect to expression. The risk of false positives can
therefore become inﬂated if testing for diﬀerences in expression is
performed in the same sample used for clustering. As such, a
reliable test of diﬀerences in expression levels among clusters
would need to be performed in a new independent sample of cells.
It would also have been interesting to characterize CD8+ T cell
responses in addition to CD4+ T cells. However, we did not
conduct any clustering or analysis of inﬂuenza virus–speciﬁc CD8+
T cells because of low responding cell numbers. In this study, we
used a limited set of inﬂuenza peptides for stimulation, and it is
possible that some responses were missed. This may also explain
the lack of expansion of CD4+ T cells. Overall, the observable
responses are limited to the set of inﬂuenza peptides that we used
for stimulation.
Another interesting ﬁnding from this study was that diﬀerent
participants seemed to have diﬀerent distributions of the inﬂuenza
virus–responsive clusters (Fig. 6). Some participants had a low
abundance of both clusters, suggesting they were simply poor
responders. Of those with higher responses, there tended to be a
pattern, with a higher abundance of Cluster 3 and a lower
abundance of Cluster 4. Such variations in inﬂuenza virus–speciﬁc
clusters could be due to exposure history or other unknown host
factors. Such host diﬀerences could aﬀect diﬀerential levels of
protective responses to inﬂuenza vaccination, as seen especially in
the elderly.
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Both Clusters 3 and 4 seem to be eﬀector memory subsets with
low CCR7 and CD45RA expression (Figs. 4, 5A). Their cytokine
expression proﬁles were distinct as Cluster 3 showed high IL-2,
TNF-a, and IFN-g, whereas Cluster 4 mainly expressed IL-17
(Figs. 4, 5). These detailed analyses of Clusters 3 and 4 underscore
the role of CD4+ memory T cell subsets in inﬂuenza virus infection.
We also noted that both Cluster 3 and Cluster 4 had high
expression of CD154 or CD40L (Fig. 4). This could potentially
mean that they can help CD8+ T cell activation by dendritic
cell licensing through the CD40L/CD40 pathway (59, 60).
In addition, we also observed that Cluster 4 showed some
expression of ICOS and PD-1 compared with other clusters (Fig.
4). This suggests that these may be Tfh-like cells, although we
lacked other Tfh markers or the ability to functionally verify this.
We did not see correlations of either of these two clusters
with HAI response (data not shown). This could be due to
heterogeneity in responsiveness in the sampled population or
because the HA peptides used to stimulate CD4+ T cell responses
represent only a subset of the HA Ags used in HAI assays.
Furthermore, the insensitivity/inaccuracy of the HAI assay,
interval-censoring of serial dilution data, or the complexity of
factors, including participant vaccine history and individual
variation, and missing data could inﬂuence results for HAI
titers. In any case, these inﬂuenza virus–speciﬁc memory
T cells might contribute to protection from disease. This is in
accordance with previous studies that have shown that they
play a protective role, even in the absence of B cells and CD8+
T cells (61).
Clusters 1, 2, 5, and 6 were not inﬂuenza virus responsive in that
they did not signiﬁcantly increase in abundance with inﬂuenza
virus peptide stimulation (Table IV). These clusters also did not
increase signiﬁcantly after inﬂuenza vaccination. Most of these
clusters were very rare (Table III), and therefore, we may not have
collected enough cells to ﬁnd signiﬁcant diﬀerences from
background. It was previously shown that cells producing
cytokines in the absence of in vitro stimulation are biased toward
a late eﬀector phenotype and are enriched in CMV-reactive
cells (in CMV-positive individuals) (62). Cluster 6 was initially
of some interest because of an inverse correlation between
California strain HAI titer and Cluster 6 abundance at day 0 but
not day 7 (Supplemental Fig. 4). However, this correlation was
possibly driven by a single extreme value, which made it hard to
evaluate the validity of this ﬁnding. Additionally, there was some
evidence that Cluster 6 may be responsive to the inﬂuenza
vaccine, based on visual inspection of the star plots (Fig. 3).
However, the abundance of Cluster 6 did not change signiﬁcantly before and after vaccination (Fig. 2, Table IV). Cluster 6
also did not increase in abundance following inﬂuenza virus
peptide stimulation (Table IV). Heat maps from expression data
pre- and postvaccination did not show major changes (data not
shown), indicating that the star plots were possibly picking up
subtle and complex shifts in its marker expression proﬁle (34).
From the heat map, we saw that Cluster 6 had a late eﬀector
phenotype with expression of cytokines like MIP1b, TNF-a, and
IFN-g (Fig. 4). This cluster also expressed CD107a and granzyme
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Supplementary Figure S1
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Figure S1. Gating of cytokine producing cells prior to denoised ragged pruning.
Total CD4+ T cells were gated for various cytokines. Left column shows unstimulated
controls, and right column shows influenza peptide stimulated samples. Top to bottom:
IFNγ, IL-2, IL-17, GM-CSF, and TNFα. After gating each cytokine, Boolean logic
(IFNγ+ OR IL-2+ OR IL-17+ OR GM-CSF+ OR TNFα+) was used to identify any
cytokine+ CD4+ T cells. Gating shown from one representative study participant.
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Supplementary Figure S2
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Figure S2. Sampling distribution and final cluster solution after down-sampling.
(A) Sampling distribution cell counts per combination of participant, visit, and
stimulation condition following stratified random down-sampling. Proportions are of
CD4+ T cells. Since participants differ among studies and batches, counts are, more
exhaustively, per each combination of study, batch, participant, visit, and stimulation
condition. Three separate stratified random down-samplings were performed: results
shown are for the third of these three. The spike in the histogram is the result of placing
the maximum down-sampling quantity per stratum at 88 cells. Down-sampling was
designed to 1) reduce computational memory requirements and time by reducing total
quantity of cells input to DRP and 2) reduce inequality in cell counts among strata so that
strata contribute less unequally to the DRP cluster solution. All down-sampling was at ~
50% of original sample size. SD = standard deviation. Figure was generated in SAS®
ODS Graphics 9.4. (B) DRP final cluster solution derived from three stratified random
50% down-samplings. Heatmap was produced with R package heatmap3 and edited with
Windows® Paint.
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Supplementary Figure S3
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Figure S3. t-SNE plot for final cluster solution. Each datum is a single cell, labeled by
cluster assignment: 3 = blue, 4 = green, 6 = magenta. t-SNE partially recovers clusters
identified via DRP. Figure was generated using base R (www.r-project.org) and R
package tsne.
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Supplementary Figure S4
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Figure S4. Regression analysis of cluster abundance and HAI titer. HAI titer
(California strain) plotted against the proportion of cells of Cluster 6 under the influenza
peptide stimulation condition at (A) Day 0 and (B) Day 7. Each I-bar (I) denotes the
censored interval of a titer observation in the two-fold dilution series. Figure was
generated in SAS® ODS Graphics 9.4 (SAS® Institute, Cary, North Carolina, USA).

